Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers

Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers

Immunotherapy, especially the immune checkpoint inhibitors (ICIs) such as the pembrolizumab and nivolumab have contributed to significant improvements in treatment outcomes and survival of head and neck cancer (HNC) patients. Still, only a subset of patients benefits from ICIs and hence the race is...

Full description

Bibliographic Details
Main Authors: Annie Wai Yeeng Chai, Pei San Yee, Sok Ching Cheong
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-03-01
Series:Frontiers in Oncology
Subjects:
head and neck cancer
targeted therapy
immunotherapy
drug combinations
cancer genetics
immune checkpoint inhibitor (ICI)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.837835/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.837835/full

Similar Items